APOBEC3A and endometrial cancer: To estimate the potential impact of the APOBEC3A/B deletion variant on endometrial cancer risk, we compared the frequency of the APOBEC3A/B genotypes among endometrial cancer patients (1470) to those of the healthy controls (1918).